Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
Corbus Pharmaceuticals will present late-breaking data from the CRB-913 Canyon-1 Phase 1B study as a poster at Obesity Week 2026, November 14-17 in National Harbor, MD. The presentation, titled 'Efficacy, Safety, and Tolerability of CRB-913 in the Ph1b CANYON-1 Study,' will be given by Harold Bays, M.D. on November 15 from 2:30-3:30 p.m. ET.
Key figures
- Drug Name
- CRB-913
- Phase Of Trial
- Phase 1B
- Conference
- Obesity Week 2026, National Harbor, MD (Nov 14-17, 2026)
- Presentation date
- November 15, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.